Oligomerix Lands $2,000,000 Series A Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    3960 Broadway New York, NY 10032
  • Company Description
    OLIGOMERIX Inc., is a biopharmaceutical company focused on developing novel drug discovery targets and therapeutics for Alzheimer’s disease and other neurodegenerative disorders. Founded in 2006, OLIGOMERIX has filed patents on tau protein oligomers (soluble aggregates) for drug and biomarker discovery. Soluble tau has been shown to cause neuronal loss and memory impairment. Compounds inhibiting the formation of tau oligomers or disrupting tau oligomers should inhibit neurodegenerative diseases. Antibodies against tau oligomers are being developed for drug discovery, for use in biomarker assays used to demonstrate drug efficacy, and to stage disease progression.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Oligomerix’s tau protease inhibitor program, which aims to neutralize tau outside of neurons, offering a more feasible approach to drug discovery than targeting intraneuronal tau oligomer formation.
  • M&A Terms
  • Venture Investor
    Wheatley Partners
  • Venture Investor
    Durand Venture Associates
  • Venture Investor

Trending on Xconomy